Metagenomi, Inc. Hits New 52-Week Low at USD 1.13

Metagenomi, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.13 as of June 17, 2026. This significant drop highlights the company's ongoing struggles, with a staggering one-year performance decline of 81.68%, starkly contrasting with the S&P 500's positive return of 24.03% during the same period. The company's financial metrics reveal a challenging landscape. With a market capitalization of USD 50 million, Metagenomi has reported negative results for the last five consecutive quarters. Key indicators such as a return on equity of -54.59% and a debt-to-equity ratio of -0.98 further underscore its precarious financial position. Additionally, the price-to-book ratio stands at 0.31, indicating potential undervaluation relative to its assets. The stock's performance has been marked by a significant increase in raw material costs, which have surged by 104.78% year-over-year. This combination of factors has contributed to a perception of heightened risk associated with the stock, as it continues to underperform both in the short and long term.